SBIR/STTR Research Award

HUMAN MONOCLONAL ANTIBODIES TO HLA-DR DETERMINANTS

Award identifier fcbf746a84793abde0e44f958ee38f5c10fd62d5610e69cbb9b983a2b5158559Awarding agency Department of Health and Human Services

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

1986

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
GENELABS TECHNOLOGIES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE HUMAN IMMUNE RESPONSE IS GOVERNED BY ORDERED INTERACTIONS BETWEEN FUNCTIONALLY AND PHENOTYPICALLY DISTINCT LYMPOID CELLS (T CELLS AND THEIR SUBSETS, B CELLS) AND MONOCYTES IN THE CONTEXT OF IA-LIKE MOLECULES ENCODED BY THE HLA COMPLEX OF GENES. THUS,THE PRODUCTS OF THESE HLA CLASS II GENES (DP,DQ AND DR) CONTROL THE PROLIFERATIVE RESPONSE OF T CELLS IN MIXED LYMPHOCYTE REACTIONS, ANTIGEN PRESENTATION TO T CELLS BY MACROPHAGES, AND COLLABORATION BETWEEN T AND B CELLS. IN ADDITION TO INFLUENCING ALLOGRAFTSURVIVAL, ALLELES OF SPECIFIC CLASS II GENES (DQ AND DR) HAVE BEEN ASSOCIATED WITH SUSCEPTIBILITY TO A NUMBER OF DISEASES INCLUDING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), RHEUMATOID ARTHRITIS (RA), AND MULTIPLE SCLEROSIS. PHASE I OF THIS PROPOSAL SUCCESSFULLLY DEMONSTRATED THAT A HUMAN MONOCLONAL IGM ANTIBODY TO HLA-DQWL COULD BE PRODUCED. IN PHASE II, A PANEL OF HUMAN MONOCLONAL ANTI-DQ AND ANTI-DR ALLOANTIBODIES WILL BE PRODUCED. IN ADDITION THE GENES FOR THESE ANTIBODIES WILL BE MANIPULATED BY A VARIETY OF DNA CLONING TECHNIQUES TO INCREASE AFFINITY AND TO SWITCH ISOTYPES. THE GENERATION OF THESE ANTIBODIES SHOULD HAVE AN IMMEDIATED PRACTICAL IMPACT IN FACILITATING CLINICAL HLA TYPING PERFORMED TO DETERMINE TRANSPLANTATION COMPATIBILITY.FURTHER, THEIR AVAILABILITY WILL ALLOW A GREATER UNDERSTANDING OF THE SPECIFICITY AND FUNCTIONAL EFFECTS ON IMMUNE FUNCTIONS OF NORMAL AND DISEASED INDIVIDUALS. ULTIMATELY, THESE ANTIBODIES MAY BE USEFUL IN THE DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISORDERS.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.